Collection

Individual-Level Models for Economic Evaluation

Pharmacoeconomics invites the submission of papers (original research, reviews, and tutorial pieces) on developing and using individual-level models for economic evaluations for a themed issue of the journal to be published in 2025. We encourage papers from the perspectives of a variety of stakeholders including methodologists, health technology assessment bodies, payers and pharmaceutical industry. Papers developing or employing novel methods are particularly encouraged. They can be either methodological or applied.As a first step please send an abstract to chris.carswell@springer.com by August 15th 2024.

Editors

  • Salah Ghabri MSc, PhD, HDR

    Salah Ghabri is Senior Health Economist and Scientific Referent Leader in economic evaluation at the Department of Medical Evaluation at the French Authority for Health, Associate Researcher and Teacher at the University of Rennes and CNAM School. His interests revolve around economic evaluation of health interventions, economic modeling and budget impact approaches, methods of causal effect, public policies, and econometrics. His most significant scientific achievements are the analysis of uncertainty and the modeling of treatments sequences in healthcare.

  • Professor J. Jaime Caro

    J. Jaime Caro, MDCM, FRCPC, FACP, is Professor in Practice at the London School of Economics, adjunct Professor in the School of Global and Population Health at McGill University, and Honorary Professor at the Saw Swee Hock School of Public Health of the National University of Singapore. Dr. Caro is also Chief Scientist at Evidera where he advances Evidera’s leadership in developing and applying novel techniques in modeling, health economics, comparative effectiveness, epidemiology, and outcomes research.

  • Professor Jon Karnon

    Jon Karnon is Professor of Health Economics at Flinders University, Australia. He has undertaken applied economic evaluations in primary care, inpatient and outpatient hospital settings, residential care and community pharmacies. Jon has particular expertise in the use of cost-effectiveness models to estimate costs and benefits over extended time horizons and have developed and published cost-effectiveness models in a wide range of clinical areas, including frailty, cardiovascular disease, ophthalmology and cancer screening. He has a longstanding interest in the use of simulation methods for health economic evaluation.

Articles

Articles will be displayed here once they are published.